RANKL cytokine: From pioneer of the osteoimmunology era to cure for a rare disease

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Lo Iacono, Nadia ^a,b   Pangrazio, Alessandra ^a,b   Abinun, Mario ^c   Bredius, Robbert ^d   Zecca, Marco ^e   Blair, Harry C ^f   Vezzoni, Paolo ^a,b   Villa, Anna ^a,b   Sobacchi, Cristina ^a,b  

^a CNR   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e San Matteo Medical Center   (Italy)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, HUMAN;

AUTOSOMAL RECESSIVE OSTEOPOROSIS; BONE; CHELATION THERAPY; CONTINUOUS INFUSION; DISEASE EXACERBATION; DNA SEQUENCE; DOSE RESPONSE; FAILURE TO THRIVE; FRACTURE; GENE MUTATION; HEMOLYTIC ANEMIA; HEPATOSPLENOMEGALY; HUMAN; HYDROCEPHALUS; IMMUNE SYSTEM; KARYOTYPE; NERVE DECOMPRESSION; NONHUMAN; NUCLEOTIDE SEQUENCE; NYSTAGMUS; OSTEOPOROSIS; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEIZURE; VISUAL IMPAIRMENT; ANIMAL; BONE DENSITY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEOSTASIS; IMMUNOLOGY; MOUSE; MUTATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPETROSIS; PATHOLOGY; RECESSIVE GENE; ALBERS SCHOENBERG DISEASE; DRUG EFFECT;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; GENE EXPRESSION REGULATION; GENES, RECESSIVE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM; MICE; MUTATION; OSTEOCLASTS; OSTEOPETROSIS; RANK LIGAND;

EID: 84878624124     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/412768     Document Type: Review

References (72)

1. Sims N. A., Walsh N. C., Intercellular cross-talk among bone cells: new factors and pathways. Current Osteoporosis Reports 2012 10 2 109 117 10.1007/s11914-012-0096-1
2. Coccia P. F., Krivit W., Cervenka J., Clawson C., Kersey J. H., Kim T. H., Nesbit M. E., Ramsay N. K., Warkentin P. I., Teitelbaum S. L., Kahn A. J., Brown D. M., Successful bone-marrow transplantation for infantile malignant osteopetrosis. The New England Journal of Medicine 1980 302 13 701 708 2-s2.0-0018891088 (Pubitemid 10132096)
3. Gerritsen E. J., Vossen J. M., Fasth A., Friedrich W., Morgan G., Padmos A., Vellodi A., Porras O., 'Meara A O., Porta F., Bone marrow transplantation for autosomal recessive osteopetrosis. A report from the working party on inborn errors of the european bone marrow transplantation group. Journal of Pediatrics 1994 125 6, part 1 896 902 10.1016/S0022-3476(05)82004-9 (Pubitemid 24379122)
4. Driessen G. J. A., Gerritsen E. J. A., Fischer A., Fasth A., Hop W. C. J., Veys P., Porta F., Cant A., Steward C. G., Vossen J. M., Uckan D., Friedrich W., Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report. Bone Marrow Transplantation 2003 32 7 657 663 2-s2.0-12444289605 10.1038/sj.bmt.1704194 (Pubitemid 37258621)
5. Mazzolari E., Forino C., Razza A., Porta F., Villa A., Notarangelo L. D., A single-center experience in 20 patients with infantile malignant osteopetrosis. The American Journal of Hematology 2009 84 8 473 479 2-s2.0-67749093440 10.1002/ajh.21447
6. Villa A., Guerrini M. M., Cassani B., Pangrazio A., Sobacchi C., Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcified Tissue International 2009 84 1 1 12 2-s2.0-58149308297 10.1007/s00223-008-9196-4
7. Sobacchi C., Frattini A., Guerrini M. M., Abinun M., Pangrazio A., Susani L., Bredius R., Mancini G., Cant A., Bishop N., Grabowski P., Del Fattore A., Messina C., Errigo G., Coxon F. P., Scott D. I., Teti A., Rogers M. J., Vezzoni P., Villa A., Helfrich M. H., Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nature Genetics 2007 39 8 960 962 2-s2.0-34547521058 10.1038/ng2076 (Pubitemid 47185178)
8. Rho J., Takami M., Choi Y., Osteoimmunology: interactions of the immune and skeletal systems. Molecular Cell 2004 17 1 1 9 (Pubitemid 39137036)
9. Takayanagi H., New developments in osteoimmunology. Nature Reviews Rheumatology 2012 8 11 684 689 10.1038/nrrheum.2012.167
10. Hanada R., Leibbrandt A., Hanada T., Kitaoka S., Furuyashiki T., Fujihara H., Trichereau J., Paolino M., Qadri F., Plehm R., Klaere S., Komnenovic V., Mimata H., Yoshimatsu H., Takahashi N., von Haeseler A., Bader M., Kilic S. S., Ueta Y., Pifl C., Narumiya S., Penninger J. M., Central control of fever and female body temperature by RANKL/RANK. Nature 2009 462 7272 505 509 2-s2.0-70849096810 10.1038/nature08596
11. Hanada R., Hanada T., Sigl V., Schramek D., Penninger J. M., RANKL/RANK-beyond bones. Journal of Molecular Medicine 2011 89 7 647 656 2-s2.0-79959936606 10.1007/s00109-011-0749-z
12. Lacey D. L., Boyle W. J., Simonet W. S., Kostenuik P. J., Dougall W. C., Sullivan J. K., San Martin J., Dansey R., Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nature Reviews Drug Discovery 2012 11 5 401 419 10.1038/nrd3705
13. Anderson D. M., Maraskovsky E., Billingsley W. L., Dougall W. C., Tometsko M. E., Roux E. R., Teepe M. C., DuBose R. F., Cosman D., Galibert L., A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997 390 6656 175 179 2-s2.0-0030714605 10.1038/36593 (Pubitemid 27507987)
14. Wong B. R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F. S., Frankel W. N., Lee S. Y., Choi Y., TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. The Journal of Biological Chemistry 1997 272 40 25190 25194 2-s2.0-14444272043 10.1074/jbc.272.40.25190 (Pubitemid 27415705)
15. Lacey D. L., Timms E., Tan H. L., Kelley M. J., Dunstan C. R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y. X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W. J., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 2 165 176 10.1016/S0092-8674(00)81569-X (Pubitemid 28180851)
16. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S. I., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the United States of America 1998 95 7 3597 3602 2-s2.0-0032584208
17. Ikeda T., Kasai M., Utsuyama M., Hirokawa K., Determination of three isoforms of the receptor activator of nuclear factor- B ligand and their differential expression in bone and thymus. Endocrinology 2001 142 4 1419 1426 2-s2.0-0035054126 10.1210/en.142.4.1419 (Pubitemid 32299669)
18. Lum L., Wong B. R., Josien R., Becherer J. D., Erdjument-Bromage H., Schlöndorff J., Tempst P., Choi Y., Blobel C. P., Evidence for a role of a tumor necrosis factor- α (TNF- α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. The Journal of Biological Chemistry 1999 274 19 13613 13618 2-s2.0-0033532191 10.1074/jbc.274.19.13613 (Pubitemid 29220502)
19. Hikita A., Tanaka S., Ectodomain shedding of receptor activator of NF- B ligand. Advances in Experimental Medicine and Biology 2007 602 15 21 10.1007/978-0-387-72009-8-2
20. Hikita A., Tanaka N., Yamane S., Ikeda Y., Furukawa H., Tohma S., Suzuki R., Tanaka S., Mitomi H., Fukui N., Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor- α Biochemistry and Cell Biology 2009 87 4 81 93 10.1139/o09-015
21. Lam J., Nelson C. A., Ross F. P., Teitelbaum S. L., Fremont D. H., Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. Journal of Clinical Investigation 2001 108 7 971 979 2-s2.0-0034784606 10.1172/JCI200113890 (Pubitemid 32946071)
22. Ito S., Wakabayashi K., Ubukata O., Hayashi S., Okada F., Hata T., Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-Å resolution. The Journal of Biological Chemistry 2002 277 8 6631 6636 2-s2.0-0037155157 10.1074/jbc.M106525200 (Pubitemid 34968464)
23. Liu C., Walter T. S., Huang P., Zhang S., Zhu X., Wu Y., Wedderburn L. R., Tang P., Owens R. J., Stuart D. I., Ren J., Gao B., Structural and functional insights of RANKL-RANK interaction and signaling. Journal of Immunology 2010 184 12 6910 6919 2-s2.0-77953623660 10.4049/jimmunol.0904033
24. Ta H. M., Nguyen G. T. T., Jin H. M., Choi J., Park H., Kim N., Hwang H. Y., Kim K. K., Structure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proceedings of the National Academy of Sciences of the United States of America 2010 107 47 20281 20286 2-s2.0-78650550815 10.1073/pnas.1011686107
25. Luan X., Lu Q., Jiang Y., Zhang S., Wang Q., Yuan H., Zhao W., Wang J., Wang X., Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. Journal of Immunology 2012 189 1 245 252 10.4049/jimmunol. 1103387
26. Nelson C. A., Warren J. T., Wang M. W., Teitelbaum S. L., Fremont D. H., RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure 2012 20 11 1971 1982 10.1016/j.str.2012.08.030
27. Kartsogiannis V., Zhou H., Horwood N. J., Thomas R. J., Hards D. K., Quinn J. M. W., Niforas P., Ng K. W., Martin T. J., Gillespie M. T., Localization of RANKL (receptor activator of NF B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999 25 5 525 534 2-s2.0-0032836854 10.1016/S8756-3282(99)00214-8 (Pubitemid 29469458)
28. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., Sakai H., Protein expression and functional difference of membrane-bound and soluble receptor activator of NF- B ligand: modulation of the expression by osteotropic factors and cytokines. Biochemical and Biophysical Research Communications 2000 275 3 768 775 2-s2.0-0034618580 10.1006/bbrc.2000.3379
29. O'Brien C. A., Control of RANKL gene expression. Bone 2010 46 4 911 919 2-s2.0-77950537989 10.1016/j.bone.2009.08.050
30. Atkins G. J., Findlay D. M., Osteocyte regulation of bone mineral: a little give and take. Osteoporosis International 2012 23 8 2067 2079 10.1007/s00198-012-1915-z
31. O'Brien C. A., Nakashima T., Takayanagi H., Osteocyte control of osteoclastogenesis. Bone 2013 54 2 258 263 10.1016/j.bone.2012.08.121
32. Xiong J., O'Brien C. A., Osteocyte RANKL: new insights into the control of bone remodeling. Journal of Bone and Mineral Research 2012 27 3 499 505 10.1002/jbmr.1547
33. Fu Q., Manolagas S. C., O'Brien C. A., Parathyroid hormone controls receptor activator of NF- B ligand gene expression via a distant transcriptional enhancer. Molecular and Cellular Biology 2006 26 17 6453 6468 2-s2.0-33747792713 10.1128/MCB.00356-06 (Pubitemid 44277886)
34. Galli C., Zella L. A., Fretz J. A., Fu Q., Pike J. W., Weinstein R. S., Manolagas S. C., O'Brien C. A., Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor- B ligand gene reduces bone remodeling and increases bone mass. Endocrinology 2008 149 1 146 153 2-s2.0-37549006425 10.1210/en.2007-0734
35. Takahashi N., Maeda K., Ishihara A., Uehara S., Kobayashi Y., Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. Frontiers in Bioscience 2011 16 21 30 10.2741/3673
36. Crockett J. C., Mellis D. J., Scott D. I., Helfrich M. H., New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporosis International 2011 22 1 1 20 2-s2.0-78651479733 10.1007/s00198-010-1272-8
37. Mellis D. J., Itzstein C., Helfrich M. H., Crockett J. C., The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption. Journal of Endocrinology 2011 211 2 131 143 10.1530/JOE-11-0212
38. Kong Y. Y., Yoshida H., Sarosi I., Tan H. L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A. J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C. R., Lacey D. L., Mak T. W., Boyle W. J., Penninger J. M., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999 397 6717 315 323 2-s2.0-0033611467 10.1038/16852 (Pubitemid 29061638)
39. Kim N., Odgren P. R., Kim D. K., Marks S. C. Jr., Choi Y., Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proceedings of the National Academy of Sciences of the United States of America 2000 97 20 10905 10910 2-s2.0-0034718609
40. Odgren P. R., Kim N., MacKay C. A., Mason-Savas A., Choi Y., Marks S. C. Jr., The role of RANKL (TRANCE/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue. Connective Tissue Research 2003 44 supplement 1 264 271 2-s2.0-12244307844 (Pubitemid 36395455)
41. Xiong J., Onal M., Jilka R. L., Weinstein R. S., Manolagas S. C., O'Brien C. A., Matrix-embedded cells control osteoclast formation. Nature Medicine 2011 17 10 1235 1241 10.1038/nm.2448
42. Nakashima T., Hayashi M., Fukunaga T., Kurata K., Oh-Hora M., Feng J. Q., Bonewald L. F., Kodama T., Wutz A., Wagner E. F., Penninger J. M., Takayanagi H., Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nature Medicine 2011 17 10 1231 1234 10.1038/nm.2452
43. Nakashima T., Takayanagi H., New regulation mechanisms of osteoclast differentiation. Annals of the New York Academy of Sciences 2011 1240 E13 E18 10.1111/j.1749-6632.2011.06373.x
44. Douni E., Rinotas V., Makrinou E., Zwerina J., Penninger J. M., Eliopoulos E., Schett G., Kollias G., A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF. Human Molecular Genetics 2012 21 4 784 798 10.1093/hmg/ddr510
45. Itonaga I., Sabokbar A., Sun S. G., Kudo O., Danks L., Ferguson D., Fujikawa Y., Athanasou N. A., Transforming growth factor- β induces osteoclast formation in the absence of RANKL. Bone 2004 34 1 57 64 2-s2.0-0942300653 10.1016/j.bone.2003.08.008 (Pubitemid 38142434)
46. Kim N., Kadono Y., Takami M., Lee J., Lee S. H., Okada F., Jung H. K., Kobayashi T., Odgren P. R., Nakano H., Yeh W. C., Lee S. K., Lorenzo J. A., Choi Y., Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. Journal of Experimental Medicine 2005 202 5 589 595 2-s2.0-24344433524 10.1084/jem.20050978 (Pubitemid 41248411)
47. Hemingway F., Kashima T. G., Knowles H. J., Athanasou N. A., Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT. Experimental Molecular Pathology 2013 94 2 380 385 10.1016/j.yexmp.2013.01.003
48. Dougall W. C., Glaccum M., Charrier K., Rohrbach K., Brasel K., de Smedt T., Daro E., Smith J., Tometsko M. E., Maliszewski C. R., Armstrong A., Shen V., Bain S., Cosman D., Anderson D., Morrissey P. J., Peschon J. J., Schuh J., RANK is essential for osteoclast and lymph node development. Genes and Development 1999 13 18 2412 2424 2-s2.0-0033568341 10.1101/gad.13.18.2412 (Pubitemid 29453612)
49. Li J., Sarosi I., Yan X. Q., Morony S., Capparelli C., Tan H. L., McCabe S., Elliott R., Scully S., Van G., Kaufman S., Juan S. C., Sun Y., Tarpley J., Martin L., Christensen K., McCabe J., Kostenuik P., Hsu H., Fletcher F., Dunstan C. R., Lacey D. L., Boyle W. J., RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proceedings of the National Academy of Sciences of the United States of America 2000 97 4 1566 1571 2-s2.0-12944262423 10.1073/pnas.97.4.1566 (Pubitemid 30118482)
50. Kapur R. P., Yao Z., Iida M. H. K., Clarke C. M., Doggett B., Xing L., Boyce B. F., Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine Rank. Journal of Bone and Mineral Research 2004 19 10 1689 1697 2-s2.0-21644469447 10.1359/JBMR.040713 (Pubitemid 41094332)
51. Goessl C., Katz L., Dougall W. C., Kostenuik P. J., Zoog H. B., Braun A., Dansey R., Wagman R. B., The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Annals of the New York Academy Science 2012 1263 29 40 10.1111/j.1749-6632.2012.06674.x
52. Chung P. Y., van Hul W., Paget's disease of bone: evidence for complex pathogenetic interactions. Seminars in Arthritis and Rheumatism 2012 41 5 619 641 10.1016/j.semarthrit.2011.07.005
53. Kim D., Mebius R. E., MacMicking J. D., Jung S., Cupedo T., Castellanos Y., Rho J., Wong B. R., Josien R., Kim N., Rennert P. D., Choi Y., Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. Journal of Experimental Medicine 2000 192 10 1467 1478 2-s2.0-0034694090 10.1084/jem.192.10.1467
54. Lo Iacono N., Blair H. C., Poliani P. L., Marrella V., Ficara F., Cassani B., Facchetti F., Fontana E., Guerrini M. M., Traggiai E., Schena F., Paulis M., Mantero S., Inforzato A., Valaperta S., Pangrazio A., Crisafulli L., Maina V., Kostenuik P., Vezzoni P., Villa A., Sobacchi C., Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: a new therapy for human RANKL-dependent ARO. Journal of Bone and Mineral Research 2012 27 12 2501 2510 10.1002/jbmr.1712
55. Rossi S. W., Kim M. Y., Leibbrandt A., Parnell S. M., Jenkinson W. E., Glanville S. H., McConnell F. M., Scott H. S., Penninger J. M., Jenkinson E. J., Lane P. J. L., Anderson G., RANK signals from CD4 inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. Journal of Experimental Medicine 2007 204 6 1267 1272 2-s2.0-34250336454 10.1084/jem.20062497 (Pubitemid 46919863)
56. Akiyama T., Shimo Y., Yanai H., Qin J., Ohshima D., Maruyama Y., Asaumi Y., Kitazawa J., Takayanagi H., Penninger J. M., Matsumoto M., Nitta T., Takahama Y., Inoue J. I., The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 2008 29 3 423 437 2-s2.0-51349111243 10.1016/j.immuni.2008.06.015
57. Hikosaka Y., Nitta T., Ohigashi I., Yano K., Ishimaru N., Hayashi Y., Matsumoto M., Matsuo K., Penninger J. M., Takayanagi H., Yokota Y., Yamada H., Yoshikai Y., Inoue J. I., Akiyama T., Takahama Y., The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 2008 29 3 438 450 2-s2.0-51349092893 10.1016/j.immuni.2008.06.018
58. Desanti G. E., Cowan J. E., Baik S., Parnell S. M., White A. J., Penninger J. M., Lane P. J., Jenkinson E. J., Jenkinson W. E., Anderson G., Developmentally regulated availability of RANKL and CD40 ligand reveals distinct mechanisms of fetal and adult cross-talk in the thymus medulla. Journal of Immunology 2012 189 12 5519 5526 10.4049/jimmunol.1201815
59. Loser K., Mehling A., Loeser S., Apelt J., Kuhn A., Grabbe S., Schwarz T., Penninger J. M., Beissert S., Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nature Medicine 2006 12 12 1372 1379 2-s2.0-33845543666 10.1038/nm1518 (Pubitemid 44924495)
60. Knoop K. A., Kumar N., Butler B. R., Sakthivel S. K., Taylor R. T., Nochi T., Akiba H., Yagita H., Kiyono H., Williams I. R., RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. Journal of Immunology 2009 183 9 5738 5747 2-s2.0-77950491661 10.4049/jimmunol.0901563
61. Knoop K. A., Butler B. R., Kumar N., Newberry R. D., Williams I. R., Distinct developmental requirements for isolated lymphoid follicle formation in the small and large intestine: RANKL is essential only in the small intestine. The American Journal of Pathology 2011 179 4 1861 1871 10.1016/j.ajpath.2011.06. 004
62. Kikuta J., Wada Y., Kowada T., Wang Z., Sun-Wada G. H., Nishiyama I., Mizukami S., Maiya N., Yasuda H., Kumanogoh A., Kikuchi K., Germain R. N., Ishii M., Dynamic visualization of RANKL and Th17-mediated osteoclast function. Journal of Clinical Investigations 2013 123 2 866 873 10.1172/JCI65054
63. Chan A. C., Carter P. J., Therapeutic antibodies for autoimmunity and inflammation. Nature Reviews Immunology 2012 10 5 301 316
64. Han X., Kawai T., Eastcott J. W., Taubman M. A., Bacterial-responsive B lymphocytes induce periodontal bone resorption. Journal of Immunology 2006 176 1 625 631 2-s2.0-29644446802 (Pubitemid 43023311)
65. Han X., Lin X., Seliger A. R., Eastcott J., Kawai T., Taubman M. A., Expression of receptor activator of nuclear factor- B ligand by B cells in response to oral bacteria. Oral Microbiology and Immunology 2009 24 3 190 196 2-s2.0-67449137943 10.1111/j.1399-302X.2008.00494.x
66. Onal M., Xiong J., Chen X., RANKL expression by B lymphocytes contributes to ovariectomy-induced bone loss. The Journal of Biological Chemistry 2012 287 35 29851 29860
67. Leibbrandt A., Penninger J. M., RANK/RANKL: regulators of immune responses and bone physiology. Annals of the New York Academy of Sciences 2008 1143 123 150 2-s2.0-56549098575 10.1196/annals.1443.016
68. Burgess T. L., Qian Y. X., Kaufman S., Ring B. D., Van G., Capparelli C., Kelley M., Hsu H., Boyle W. J., Dunstan C. R., Hu S., Lacey D. L., The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. Journal of Cell Biology 1999 145 3 527 538 2-s2.0-0033519221 10.1083/jcb.145.3.527 (Pubitemid 29215717)
69. Lacey D. L., Tan H. L., Lu J., Kaufman S., Van G., Qiu W., Rattan A., Scully S., Fletcher F., Juan T., Kelley M., Burgess T. L., Boyle W. J., Polverino A. J., Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. The American Journal of Pathology 2000 157 2 435 448 10.1016/S0002-9440(10)64556-7 (Pubitemid 30626907)
70. Lloyd S. A. J., Yuan Y. Y., Kostenuik P. J., Ominsky M. S., Lau A. G., Morony S., Stolina M., Asuncion F. J., Bateman T. A., Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcified Tissue International 2008 82 5 361 372 2-s2.0-45849117956 10.1007/s00223-008-9133-6
71. Yuan Y. Y., Kostenuik P. J., Ominsky M. S., Morony S., Adamu S., Simionescu D. T., Basalyga D. M., Asuncion F. J., Bateman T. A., Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporosis International 2008 19 5 625 635 2-s2.0-43149095800 10.1007/s00198-007-0509-7
72. Tomimori Y., Mori K., Koide M., Nakamichi Y., Ninomiya T., Udagawa N., Yasuda H., Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. Journal of Bone and Mineral Research 2009 24 7 1194 1205 2-s2.0-70349116967 10.1359/jbmr.090217